Partner David Rosen was quoted in a Washington Post article, “Regulators Take a Growing Interest in Drugmakers’ Moves to Protect Profits,” on March 19, 2015. The article discussed the competitive nature of patents for the prescription drug market, along with related antitrust issues. Rosen was quoted saying, “This industry is under a lot of scrutiny because the cost savings in the generic world are pretty high for the public.”
People
Related News
January 13, 2026
In the News
Louis Lehot Co-Authors 2026 M&A Technology Playbook
Foley & Lardner LLP Louis Lehot co-authored The Legal Intelligencer article, “State of Tech M&A: A 2026 Playbook for Founders Who Want to Win,” providing a practical guide for founders of emerging companies considering mergers and acquisitions.
January 6, 2026
In the News
Kyle Faget Weighs in on Pharmaceutical Industry Legal Battles
Foley & Lardner LLP partner Kyle Faget shared insight with Law360 on major legal topics affecting the pharmaceutical industry.
January 2, 2026
In the News
Judith Waltz Shares Insights on Key Health Law Developments on AHLA Podcast
Foley & Lardner LLP partner Judith Waltz hosted the American Health Law Association's Speaking of Health Law podcast to discuss major health law developments from 2025 and offer insights on trends expected in 2026.